Clinical trials: Asthma Atopic
Bronchial Asthma
OC000459 Bronchial Allergen Challenge
OC0000459 reduces inflammation in the tissues in response to allergic stimuli in patients with asthma. This clinical trial, in mildly asthmatic patients, studies the effects of OC000459 and placebo on the asthmatic response to…
- Trial name
- NCT01056692
- Testing
- OC000459
- Where
- 2 sites in United Kingdom
- Volunteers
- 20 people
- Sponsor
- Oxagen Ltd
Asthma
A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma
This is a non-confirmatory, randomized, subject and investigator blinded, placebo-controlled, parallel-design, multi-center bronchoprovocation study.
- Trial name
- NCT03138811
- Testing
- CSJ117
- Where
- 10 sites in Canada, Germany
- Volunteers
- 28 people
- Sponsor
- Novartis Pharmaceuticals
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis. MM09-SIT-063.
The goal of this clinical trial is to learn whether EP-088_MM09 works to treat house dust mite allergy. It will also assess the treatment's safety.
- Conditions
- Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma
- Trial name
- MM09-SIT-063 (NCT07904052)
- Testing
- EP-088_MM09
- Where
- 16 sites in Portugal, Spain
- Volunteers
- 250 people
- Sponsor
- Inmunotek S.L.
Allergic Asthma
Subcutaneous-Sublingual Immunotherapy With Depigmented and Polymerized Dermatophagoides Pteronyssinus Allergen Extract
The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract Dermatophagoides pteronyssinus in children with allergic asthma due to this mite
- Trial name
- NCT00622362
- Testing
- DEPIGOID Dermatophagoides pteronyssinus, Polymerized TOL of Dermatophagoides pteronyssinus
- Where
- Spain
- Volunteers
- 3 people
- Sponsor
- Laboratorios Leti, S.L.
Allergy
Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Immunogenicity of QGE031 in Japanese Atopic Male Subjects
This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics and immunogenicity of QGE031 in Japanese atopic male subjects in order to determine the eligibility of Japanese patients in subsequent clinical…
- Trial name
- NCT01596712
- Testing
- QGE031
- Where
- Japan
- Volunteers
- 209 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Rhinitis, Allergic, Rhinoconjunctivitis
Efficacy and Safety Evaluation for the Treatment of Allergy Against Grass and Olive Pollen
Prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial of efficacy and safety with subcutaneous immunotherapy in patients with mild to moderate rhinitis / rhinoconjunctivitis with or without mild to…
- Conditions
- Rhinitis, Allergic, Rhinoconjunctivitis, Asthma, Allergic
- Trial name
- NCT04891237
- Testing
- 10,000 MG01 + 10,000 T517, 30,000 MG01 + 10,000 T517
- Where
- 32 sites in Spain
- Volunteers
- 180 people
- Sponsor
- Inmunotek S.L.
Atopic Asthma
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of ADC3680B in Subjects With Partly Controlled Atopic Asthma
This study is to examine the safety, tolerability, pharmacokinetics and functional activity of ADC3680B administered once daily for 28 days in subjects with partly controlled atopic asthma.
- Trial name
- NCT01448954
- Testing
- ADC3680B oral
- Where
- 2 sites in United Kingdom
- Volunteers
- 36 people
- Sponsor
- Pulmagen Therapeutics
Allergic Asthma
A Phase IIa Study of Subcutaneous AER 001 on Antigen Challenge In Atopic Asthmatic Subjects (28 Day Study)
This is a single center, double-blind, randomised parallel group design study to investigate the effects of AER 001 on the late phase asthmatic resonse in asthmatic subjects.
- Trial name
- NCT00535028
- Testing
- AER 001
- Where
- United Kingdom
- Volunteers
- 24 people
- Sponsor
- Aerovance, Inc.
Asthma, House Dust Mite Allergy
Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma
The purpose of this study is to investigate the efficacy and safety of different doses of sublingual tablets of house dust mite allergen extracts as compared to placebo in adults with house dust mite-associated allergic asthma.
- Trial name
- NCT01930461
- Testing
- SLIT tablets of HDM allergen extracts, 3 different doses (A), SLIT tablets of HDM allergen extracts, 3 different doses (B), SLIT tablets of HDM allergen extracts, 3 different doses (C)
- Where
- 5 sites in France, Germany and 1 more
- Volunteers
- 386 people
- Sponsor
- Stallergenes Greer
Rhinitis, Rhinoconjunctivitis
Safety, Tolerability and Efficacy of the Depigmented Modified Allergen Extract of Two Mites in Subjects With Allergic Rhinitis or Rhinoconjunctivitis, With Controlled Allergic Asthma
This is an open-label, non-controlled, non-randomised, prospective safety study in patients with rhinitis or allergic rhinoconjunctivitis, with controlled asthma, and clinically relevant sensitisation to dust mites from the…
- Conditions
- Rhinitis, Rhinoconjunctivitis, Asthma
- Trial name
- NCT02340130
- Testing
- DP/MG/14-1, DP/MG/14-2
- Where
- 3 sites in Spain
- Volunteers
- 57 people
- Sponsor
- Laboratorios Leti, S.L.
Asthma
Efficacy, Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of Oral Administration of AIM-102 in Patients With Mild to Moderate Allergic Asthma
This is a Phase II, double-blind, placebo-controlled, cross-over trial to evaluate the efficacy of AIM-102 for the treatment of allergen-induced asthma.
- Trial name
- NCT01501942
- Testing
- AIM-102, D-cyclohexylalanine-D-glutamic-glycine tripeptide, Buffered Saline
- Where
- 2 sites in Canada
- Volunteers
- 11 people
- Sponsor
- AIM Therapeutics Inc.
Allergic Asthma, Allergy
Validation of Strasbourg Environmental Exposure Chamber ALYATEC in Cat Allergic Subjects With Asthma
This is a randomized, double blind, cross-over study designed to determine the concentration of airborne cat allergen inducing bronchial response in asthmatic subjects allergic to cat, during allergen exposures in the Alyatec…
- Conditions
- Allergic Asthma, Allergy, Allergy to Cats
- Trial name
- NCT04678063
- Testing
- Exposure to dose A and dose B of cat allergen, Exposure to a single dose of cat allergen
- Where
- France
- Volunteers
- 31 people
- Sponsor
- Alyatec
Allergic Asthma
Evaluate the Efficacy and Safety of FB825 in Adult With Allergic Asthma
This is a randomized, placebo-controlled and double-blind study to evaluate the efficacy and safety of FB825 in adult patients with moderate-to-severe allergic asthma.
- Trial name
- NCT05008965
- Testing
- FB825
- Where
- 13 sites in Taiwan
- Volunteers
- 100 people
- Sponsor
- Oneness Biotech Co., Ltd.
Asthma, Perennial Allergy
Clinical Effects of Temperature Controlled Laminar Airflow (TLA)
The purpose of this study is to determine whether clean air administered to the breathing zone with Temperature controlled Laminar Airflow (TLA) during night is effective in the treatment of perennial allergic asthma.
- Trial name
- NCT00987064
- Testing
- Temperature controlled Laminar Airflow (Protexo)
- Where
- 2 sites in Sweden
- Volunteers
- 28 people
- Sponsor
- Airsonett AB
Allergic Rhinitis, Allergic Rhinoconjunctivitis
Specific Immunotherapy With Mannan-Conjugated Allergoids for HDM-Allergic Rhinitis/Rhinoconjunctivitis_MM09-SIT-063.
The goal of this clinical trial is to learn whether EP-088_MM09 works to treat house dust mite allergy. It will also assess the treatment's safety.
- Conditions
- Allergic Rhinitis, Allergic Rhinoconjunctivitis, Allergic Asthma
- Trial name
- NCT07904195
- Testing
- EP-088_MM09
- Where
- 16 sites in Portugal, Spain
- Volunteers
- 250 people
- Sponsor
- Inmunotek S.L.
Asthma
A Study to Evaluate the Effect of a Single-Dose Intravenous Administration of MEDI-528
To evaluate the effect of MEDI-528 in adults with atopic asthma.
- Trial name
- NCT00483041
- Testing
- MEDI528 9 mg/kg
- Where
- 4 sites in United States
- Volunteers
- 11 people
- Sponsor
- MedImmune LLC
Asthma
Omalizumab in Adult and Adolescent Patients With Severe Persistent Allergic Asthma
Omalizumab will be given as add-on treatment to optimized asthma therapy in patients with severe persistent asthma, who demonstrate inadequate asthma symptom control.
- Trial name
- NCT00264849
- Testing
- Omalizumab, Optimized asthma therapy
- Where
- 17 sites in Belgium, Canada and 15 more
- Volunteers
- 406 people
- Sponsor
- Novartis
Allergic Rhinitis Due to House Dust Mite, Allergic Asthma
Evaluate Measurement Instruments Relevance in Assessing Effectiveness of ACARIZAX® in House Dust Mite Allergic Rhinitis
The study is a single-center, observational design with a 12-month duration. Approximately 100 Chinese adult (18-65 years old) and adolescent (12-17 years old) with moderate to severe house dust mite (HDM) allergic rhinitis (AR)…
- Trial name
- NCT06151938
- Testing
- Standardised allergen extract from house dust mites
- Where
- China
- Volunteers
- 100 people
- Sponsor
- ALK-Abelló A/S
Allergic Asthma, Uncontrolled Moderate to Severe
Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma
The purpose of this study is to evaluate the efficacy and safety of Omalizumab produced by CinnaGen compared with Xolair® (Genentech, Inc., USA And Novartis Pharmaceuticals Corp, Switzerland) in subjects with uncontrolled…
- Trial name
- NCT05813470
- Testing
- Omalizumab (CinnaGen), Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)
- Where
- 22 sites in Iran
- Volunteers
- 256 people
- Sponsor
- Cinnagen
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences